Mishcon de Reya has advised Centauri Therapeutics on its £6 million Series A extension investment from AMR Action Fund, supporting the company’s continued development of novel immunotherapies targeting hard-to-treat bacterial infections.
Centauri, an immunotherapy company based in Alderley Park, Cheshire, is advancing CTX‑187 – its lead clinical candidate – towards Phase I clinical studies. CTX‑187 is a transformative immunotherapeutic approach designed to combat Gram‑negative infections in even the most vulnerable patients, based on Centauri’s proprietary Alphamer platform. The £6 million investment from AMR Action Fund sits within Centauri’s wider £30 million Series A round and reflects global concerns around the growing global burden of antimicrobial resistance.
Centauri’s leadership team (predominantly female‑led) continues to focus on bringing forward new antimicrobial innovations at a time of acute clinical need.
Mishcon de Reya has advised Centauri for nearly a decade, supporting the business from early‑stage development through to major fundraising milestones. Partner Hayley Cross and Associate Emma O’Rourke lead the company's corporate transactions, together with a wider team across the firm's Life Sciences Group.
Hayley Cross commented: “We are delighted to have supported Centauri once again on this important milestone. The company’s work is both pioneering and urgently needed and it is an absolute pleasure to work with Jen and her team. This latest investment gives Centauri a fantastic platform for future development and the Mishcon team looks forward to continuing to support them on the journey ahead."